Triple

T9807402
Position Surface form Disambiguated ID Type / Status
Subject programmed death-ligand 1 E238185 entity
Predicate targetOfDrug P37016 FINISHED
Object avelumab
Avelumab is a human monoclonal antibody immunotherapy drug used to treat certain cancers by blocking the PD-L1 immune checkpoint pathway.
 E822413 NE FINISHED

How this triple was built (4 steps)

Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.

NER Named-entity recognition gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: avelumab | Statement: [programmed death-ligand 1, targetOfDrug, avelumab]
NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07 
Target entity: avelumab
Context triple: [programmed death-ligand 1, targetOfDrug, avelumab]
  • A. ansuvimab
    Ansuvimab is a monoclonal antibody used as a therapeutic treatment for infection caused by Zaire ebolavirus (Ebola virus).
  • B. Imfinzi
    Imfinzi is a prescription immunotherapy drug (durvalumab) developed by AstraZeneca, primarily used to treat certain types of lung and bladder cancers by helping the immune system attack cancer cells.
  • C. Libtayo
    Libtayo is a monoclonal antibody immunotherapy drug used primarily to treat certain types of advanced skin and lung cancers by targeting the PD-1 pathway.
  • D. Verzenio
    Verzenio is a prescription cancer medication (abemaciclib) used primarily to treat certain types of hormone receptor–positive, HER2-negative breast cancer.
  • E. Alecensa
    Alecensa is a targeted cancer therapy (alectinib) primarily used to treat ALK-positive non-small cell lung cancer.
  • F. None of above. chosen
  • G. Unsure - the case is ambiguous/there is not enough information to decide.
NEDg Description generation gpt-5.1
Instruction
Generate a one-sentence description of the target entity. 
You are given a context triple in the form (subject, predicate, object), where the object is the target entity. 
# Instructions
Use the triple to infer relevant information about the entity. Describe the entity based on what is most defining, well-known. 
Avoid repeating the information from the triple, unless really essential.
# Response Format
Return only the sentence: "Description: [one-sentence description of the target entity]"
Input
Entity: avelumab
Triple: [programmed death-ligand 1, targetOfDrug, avelumab]
Generated description
Avelumab is a human monoclonal antibody immunotherapy drug used to treat certain cancers by blocking the PD-L1 immune checkpoint pathway.
NED2 Entity disambiguation (via description) gpt-5-mini-2025-08-07 
Target entity: avelumab
Target entity description: Avelumab is a human monoclonal antibody immunotherapy drug used to treat certain cancers by blocking the PD-L1 immune checkpoint pathway.
  • A. ansuvimab
    Ansuvimab is a monoclonal antibody used as a therapeutic treatment for infection caused by Zaire ebolavirus (Ebola virus).
  • B. Imfinzi
    Imfinzi is a prescription immunotherapy drug (durvalumab) developed by AstraZeneca, primarily used to treat certain types of lung and bladder cancers by helping the immune system attack cancer cells.
  • C. Libtayo
    Libtayo is a monoclonal antibody immunotherapy drug used primarily to treat certain types of advanced skin and lung cancers by targeting the PD-1 pathway.
  • D. Verzenio
    Verzenio is a prescription cancer medication (abemaciclib) used primarily to treat certain types of hormone receptor–positive, HER2-negative breast cancer.
  • E. Alecensa
    Alecensa is a targeted cancer therapy (alectinib) primarily used to treat ALK-positive non-small cell lung cancer.
  • F. None of above. chosen

Provenance (5 batches)

The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.

Step Stage Batch ID Status When
creating Elicitation batch_69ca84defac48190abc1148804f184c1 completed March 30, 2026, 2:12 p.m.
NER Named-entity recognition batch_69cdab7ddaac8190a5584a5c863fbaa3 completed April 1, 2026, 11:34 p.m.
NED1 Entity disambiguation (via context triple) batch_69d1cc57119881909616d835def02fc9 completed April 5, 2026, 2:43 a.m.
NEDg Description generation batch_69d1cd137b30819089356b9fbc265d17 completed April 5, 2026, 2:46 a.m.
NED2 Entity disambiguation (via description) batch_69d1cd8fcf488190bc72a99e81fb618b completed April 5, 2026, 2:48 a.m.
Created at: March 30, 2026, 8:29 p.m.